Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life

Authors: Nicholas Bascou, Anthony DeRenzo, Michele D. Poe, Maria L. Escolar

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Krabbe disease is a rare neurodegenerative disorder caused by a deficiency in the lysosomal enzyme galactocerebrosidase. Patients with Krabbe disease present with a variable disease course depending on their age of onset. The purpose of this prospective cohort study was to characterize the natural progression of Krabbe disease in a large group of patients with disease onset between 6 and 36 months of life who were evaluated with a standardized protocol.

Methods

All patients with Krabbe disease who had onset between 6 and 36 months of age and were prospectively evaluated between 2000 to 2017 were included. Standardized neurodevelopmental, physical, and neurological examinations were performed. Other assessments included neuroradiologic and neurophysiologic tests, enzyme level, cerebrospinal fluid analysis, and GALC pathogenic variants when available. Descriptive statistics were used for analysis. Survival curve was estimated using the Kaplan–Meier method.

Results

Thirty-five patients (26 boys, 9 girls) with disease onset between 6 and 36 months of age were evaluated. Median age at symptom onset was 11.5 months, with a median delay of 3.5 months between onset of symptoms and diagnosis. Of the 32 symptomatic patients, 23 presented with initial signs or symptoms of disease between 6 and 12 months of life; nine presented after 12 months. The most common initial signs and symptoms were loss of acquired developmental milestones, irritability, abnormal gait, motor delay, and abnormal muscle tone. The most common magnetic resonance imaging abnormality was increased T2 signal in the periventricular white matter. Nerve conduction velocity results were abnormal for 21 of 24 patients. Patients with onset after 12 months had less peripheral nerve involvement and slower disease progression. Abnormal cerebrospinal fluid protein levels were obtained for 13 of 16 symptomatic children. Protein levels were normal in all asymptomatic children.

Conclusions

Based on our findings, we propose reclassifying the group of patients with onset ≤12 months as infantile and the > 12 month group as late-infantile. Patients with onset > 12 months are more likely to benefit from hematopoietic stem cell transplantation. The proposed change in classifications will allow physicians to improve their ability to recognize and diagnose patients and more precisely assess potential treatment effects after transplantation.
Literature
1.
go back to reference Suzuki K. Globoid cell leukodystrophy (Krabbe’s disease): update. J Child Neurol. 2003;18(9):595–603.CrossRefPubMed Suzuki K. Globoid cell leukodystrophy (Krabbe’s disease): update. J Child Neurol. 2003;18(9):595–603.CrossRefPubMed
2.
go back to reference Wenger DA, Rafi MA, Luzi P, et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab. 2000;70:1–9.CrossRefPubMed Wenger DA, Rafi MA, Luzi P, et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab. 2000;70:1–9.CrossRefPubMed
3.
go back to reference Moser HW. Peripheral nerve involvement in Krabbe disease: a guide to therapy selection and evaluation. Neurology. 2006;67:201–2.CrossRefPubMed Moser HW. Peripheral nerve involvement in Krabbe disease: a guide to therapy selection and evaluation. Neurology. 2006;67:201–2.CrossRefPubMed
4.
go back to reference Castelvetri LC, Givogri MI, Zhu H, et al. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol. 2011;122:35–48.CrossRefPubMedPubMedCentral Castelvetri LC, Givogri MI, Zhu H, et al. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol. 2011;122:35–48.CrossRefPubMedPubMedCentral
6.
go back to reference Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain Dev. 2009;31(7):485–7.CrossRefPubMed Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain Dev. 2009;31(7):485–7.CrossRefPubMed
7.
go back to reference Brodsky MC, Hunter JS. Positional ocular flutter and thickened optic nerves as sentinel signs of Krabbe disease. J AAPOS. 2011;15(6):595–7.CrossRefPubMed Brodsky MC, Hunter JS. Positional ocular flutter and thickened optic nerves as sentinel signs of Krabbe disease. J AAPOS. 2011;15(6):595–7.CrossRefPubMed
8.
go back to reference Morse LE, Rosman NP. Myoclonic seizures in Krabbe disease: a unique presentation in late-onset type. Pediatr Neurol. 2006;35(2):154–7.CrossRefPubMed Morse LE, Rosman NP. Myoclonic seizures in Krabbe disease: a unique presentation in late-onset type. Pediatr Neurol. 2006;35(2):154–7.CrossRefPubMed
9.
go back to reference Wenger DA, Suzuki K, Suzuki Y, Suzuki K. Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe disease). In: Scriver CR, Sly WS, Childs B, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3669–94. Wenger DA, Suzuki K, Suzuki Y, Suzuki K. Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe disease). In: Scriver CR, Sly WS, Childs B, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3669–94.
10.
go back to reference Duffner PK, Jalal K, Carter RL. The Hunter's hope Krabbe family database. Pediatr Neurol. 2009;40(1):13–8.CrossRefPubMed Duffner PK, Jalal K, Carter RL. The Hunter's hope Krabbe family database. Pediatr Neurol. 2009;40(1):13–8.CrossRefPubMed
11.
go back to reference Duffner PK, Barczykowski A, Jalal K, Yan L, Kay DM, Carter RL. Early infantile Krabbe disease: results of the world-wide Krabbe registry. Pediatr Neurol. 2011;45(3):141–8.CrossRefPubMed Duffner PK, Barczykowski A, Jalal K, Yan L, Kay DM, Carter RL. Early infantile Krabbe disease: results of the world-wide Krabbe registry. Pediatr Neurol. 2011;45(3):141–8.CrossRefPubMed
12.
go back to reference Wenger DA, Escolar ML, Luzi P, Rafi MA. Krabbe disease (globoid cell leukodystrophy). In: Scriver’s The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID); 2013. Wenger DA, Escolar ML, Luzi P, Rafi MA. Krabbe disease (globoid cell leukodystrophy). In: Scriver’s The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID); 2013.
13.
go back to reference Duffner PK, Barczykowski A, Kay DM, Jalal K, Yan L, Abdelhalim A, Gill S, Gill AL, Carter R. Later onset phenotypes of Krabbe disease: results of the world-wide registry. Pediatr Neurol. 2012;46(5):298–306.190.CrossRefPubMed Duffner PK, Barczykowski A, Kay DM, Jalal K, Yan L, Abdelhalim A, Gill S, Gill AL, Carter R. Later onset phenotypes of Krabbe disease: results of the world-wide registry. Pediatr Neurol. 2012;46(5):298–306.190.CrossRefPubMed
14.
go back to reference Zhao S, Zhan X, Wang Y, Ye J, Han L, Qiu W, Gao X, Gu X, Zhang H. Large-scale study of clinical and biochemical characteristics of Chinese patients diagnosed with Krabbe disease. Clin Genet. 2018;93(2):248–54.CrossRefPubMed Zhao S, Zhan X, Wang Y, Ye J, Han L, Qiu W, Gao X, Gu X, Zhang H. Large-scale study of clinical and biochemical characteristics of Chinese patients diagnosed with Krabbe disease. Clin Genet. 2018;93(2):248–54.CrossRefPubMed
15.
go back to reference Shao Y, Choquet K, Piana RL, et al. B. Mutations in GALC cause late-onset Krabbe disease with predominant cerebellar ataxia. Neurogenetics. 2016;17(2):137–41.CrossRefPubMed Shao Y, Choquet K, Piana RL, et al. B. Mutations in GALC cause late-onset Krabbe disease with predominant cerebellar ataxia. Neurogenetics. 2016;17(2):137–41.CrossRefPubMed
16.
go back to reference Wenger DA, Luzi P, Rafi MA. Krabbe disease: are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations? Mol Genet Metab. 2014;111(3):307–8.CrossRefPubMed Wenger DA, Luzi P, Rafi MA. Krabbe disease: are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations? Mol Genet Metab. 2014;111(3):307–8.CrossRefPubMed
17.
go back to reference Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain. 1916;39(1–2):74–114.CrossRef Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain. 1916;39(1–2):74–114.CrossRef
18.
go back to reference Hagberg B, Kollberg H, Sourander P, Akesson HO. Infantile globoid cell leukodystrophy (Krabbe’s disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropadiatrie. 1969;1:74–88.CrossRefPubMed Hagberg B, Kollberg H, Sourander P, Akesson HO. Infantile globoid cell leukodystrophy (Krabbe’s disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropadiatrie. 1969;1:74–88.CrossRefPubMed
19.
go back to reference Aldosari M, Altuwaijri M, Husain AM. Brain-stem auditory and visual evoked potentials in children with Krabbe disease. Clin Neurophysiol. 2004;115(7):1653–6.CrossRefPubMed Aldosari M, Altuwaijri M, Husain AM. Brain-stem auditory and visual evoked potentials in children with Krabbe disease. Clin Neurophysiol. 2004;115(7):1653–6.CrossRefPubMed
20.
go back to reference Husain AM, Altuwaijri M, Aldosari M. Krabbe disease neurophysiologic studies and MRI correlations. Neurology. 2004;63(4):617–20.CrossRefPubMed Husain AM, Altuwaijri M, Aldosari M. Krabbe disease neurophysiologic studies and MRI correlations. Neurology. 2004;63(4):617–20.CrossRefPubMed
21.
go back to reference Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. New Engl J Med. 2005;352(20):2069–81.CrossRefPubMed Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. New Engl J Med. 2005;352(20):2069–81.CrossRefPubMed
22.
go back to reference Lim ZY, Ho AY, Abrahams S, et al. Sustained neurological improvement following reduced-intensity conditioning allogenic hematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transpl. 2008;41(9):831–2.CrossRef Lim ZY, Ho AY, Abrahams S, et al. Sustained neurological improvement following reduced-intensity conditioning allogenic hematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transpl. 2008;41(9):831–2.CrossRef
23.
go back to reference Escolar ML, Yelin K, Poe MD. Neurodevelopmental outcomes of children with infantile Krabbe disease treated with umbilical cord blood transplantation: 10 years of follow up. CML: Lysosomal Storage Disease. 2006;6(3):72–9. Escolar ML, Yelin K, Poe MD. Neurodevelopmental outcomes of children with infantile Krabbe disease treated with umbilical cord blood transplantation: 10 years of follow up. CML: Lysosomal Storage Disease. 2006;6(3):72–9.
24.
go back to reference Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics. 2006;118(3):e879–89.CrossRefPubMed Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics. 2006;118(3):e879–89.CrossRefPubMed
25.
go back to reference Lantos JD. Dangerous and expensive screening and treatment for rare childhood diseases: the case of krabbe disease. Dev Disabil Res Rev. 2011;17(1):15–8.CrossRefPubMedPubMedCentral Lantos JD. Dangerous and expensive screening and treatment for rare childhood diseases: the case of krabbe disease. Dev Disabil Res Rev. 2011;17(1):15–8.CrossRefPubMedPubMedCentral
27.
go back to reference Wasserstein MP, Andriola M, Arnold G, Aron A, Duffner P, Erbe RW, Escolar ML, Estrella L, Galvin-Parton P, Iglesias A, Kay DM. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York state. Genet Med. 2016;18(12):1235.CrossRefPubMed Wasserstein MP, Andriola M, Arnold G, Aron A, Duffner P, Erbe RW, Escolar ML, Estrella L, Galvin-Parton P, Iglesias A, Kay DM. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York state. Genet Med. 2016;18(12):1235.CrossRefPubMed
28.
go back to reference Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA, Ficicioglu C, Waldman AT, Burton BK, Hopkins PV, Orsini JJ. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13(1):30.CrossRefPubMedPubMedCentral Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA, Ficicioglu C, Waldman AT, Burton BK, Hopkins PV, Orsini JJ. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13(1):30.CrossRefPubMedPubMedCentral
30.
go back to reference Biffi A, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet. 2011;20(1):R42–53.CrossRefPubMed Biffi A, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet. 2011;20(1):R42–53.CrossRefPubMed
31.
go back to reference Matthes F, Andersson C, Stein A, et al. Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy. Exp Neurol. 2015;271:36–45.CrossRefPubMed Matthes F, Andersson C, Stein A, et al. Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy. Exp Neurol. 2015;271:36–45.CrossRefPubMed
32.
go back to reference Martin HR, Poe MD, Reinhartsen D, et al. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr Suppl. 2008;97:69–75.CrossRef Martin HR, Poe MD, Reinhartsen D, et al. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr Suppl. 2008;97:69–75.CrossRef
33.
go back to reference Bruininks RH, Woodcock RW, Weatherman RF, Hill BK. Scales of independent behavior-revised. Itasca: Riverside Publishing; 1996. Bruininks RH, Woodcock RW, Weatherman RF, Hill BK. Scales of independent behavior-revised. Itasca: Riverside Publishing; 1996.
34.
go back to reference Folio MR, Fewell RR. Peabody developmental motor scales, 2nd ed. Austin: Pro-Ed; 2000. Folio MR, Fewell RR. Peabody developmental motor scales, 2nd ed. Austin: Pro-Ed; 2000.
35.
go back to reference Mullen EM. Mullen scales of early learning AGS edition. Circle Pines: American Guidance Service. Inc.; 1995. Mullen EM. Mullen scales of early learning AGS edition. Circle Pines: American Guidance Service. Inc.; 1995.
36.
go back to reference Russell DJ, Rosenbaum PL, Wright M, Avery LM. Gross motor function measure (GMFM-66 and GMFM-88) User's manual. 2nd ed. London: Mac Keith Press; 2013. Russell DJ, Rosenbaum PL, Wright M, Avery LM. Gross motor function measure (GMFM-66 and GMFM-88) User's manual. 2nd ed. London: Mac Keith Press; 2013.
37.
go back to reference Burger-Caplan R, Saulnier CA, Sparrow SS. Vineland adaptive behavior scales. InEncyclopedia of clinical neuropsychology: Springer International Publishing; 2018. p. 1–5. Burger-Caplan R, Saulnier CA, Sparrow SS. Vineland adaptive behavior scales. InEncyclopedia of clinical neuropsychology: Springer International Publishing; 2018. p. 1–5.
38.
go back to reference Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics Vital Health Stat. 2002;11:1. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics Vital Health Stat. 2002;11:1.
39.
go back to reference den Dunnen JT. Describing sequence variants using HGVS nomenclature. InGenotyping. New York: Humana press; 2017. p. 243–51. den Dunnen JT. Describing sequence variants using HGVS nomenclature. InGenotyping. New York: Humana press; 2017. p. 243–51.
Metadata
Title
A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life
Authors
Nicholas Bascou
Anthony DeRenzo
Michele D. Poe
Maria L. Escolar
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0872-9

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue